The market consensus of just 9.5% implied probability for a hantavirus vaccine approval by the end of 2026 reflects the absence of any candidate that has advanced beyond early preclinical testing. Current mRNA and DNA-based efforts targeting strains such as Andes virus and Hantaan virus have shown neutralizing antibodies in rodent models, yet none have entered human Phase I trials as of May 2026. Typical regulatory pathways for such vaccines require several additional years of safety and efficacy data, especially given the sporadic nature of hantavirus pulmonary syndrome outbreaks and the lack of established correlates of protection. Recent clusters, including the 2026 Andes virus cases aboard the MV Hondius, underscore rising incidence linked to rodent range expansion but have not triggered accelerated development programs. A realistic shift could occur only if a major outbreak prompted emergency-use authorization or massive public funding similar to prior pandemic responses.